Advertisement
Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All

The Lead

Synthetic Lethality Offers New Approach to Kill Tumor Cells

October 31, 2014 1:51 pm | News | Comments

A recent approach to treat cancer called synthetic lethality takes advantage of genetic alterations in cancer cells that make them more susceptible to certain drugs. Read more...              

TOPICS:
View Sample

FREE Email Newsletter

DDD Update

Daily news and top headlines for drug research professionals

Mouse Model Could Accelerate Ebola Treatment Research

October 31, 2014 1:36 pm | News | Comments

Researchers at the University of North Carolina at Chapel Hill and colleagues have developed the first genetic strain of mice that can be infected with Ebola and display symptoms similar to those that humans experience. Read more...     

TOPICS:

Game Changing Migraine Med to be Available November 2014

October 31, 2014 12:54 pm | News | Comments

Migranade Inc announced the new migraine medication will be available to the 36 million U.S. migraine sufferers November 2014. Read more...                    

TOPICS:

Special Report: Many Stem Cell Clinical Trials for Macular Degeneration

October 31, 2014 11:22 am | by Cynthia Fox, Science Editor | Articles | Comments

The most potent stem cells are coming to patients after helping blind (and nearly blind) mice see for years. Read more...                                                                                

TOPICS:
Advertisement

Increased Dosing of Malaria Drug in Children May Lower Infection Risk

October 31, 2014 10:27 am | News | Comments

Piperaquine is a long-acting malaria drug that kills residual parasites and decreases the risk of reinfection. A study led by Uppsala University researcher Martin Bergstrand shows that increasing the dose used in children could potentially decrease the yearly incidence of malaria by 70%. Read more... 

TOPICS:

Africans Worst Responders in Ebola Crisis

October 31, 2014 10:18 am | by Michelle Faul - Associated Press | News | Comments

The head of Africa's continental body did not get to an Ebola-hit country until last week - months after alarm bells first rang and nearly 5,000 deaths later. Read more...                               

TOPICS:

Daiichi Sankyo's Heart Drug Gets FDA Recommendation

October 31, 2014 10:11 am | News | Comments

Daiichi Sankyo announced that the FDA Cardiovascular and Renal Drugs Advisory Committee voted 9 to 1 to recommend approval of once-daily Savaysa (edoxaban) 60 mg dosing regimen for the reduction in risk of stroke and systemic embolic events (SEE) in patients with non-valvular atrial fibrillation (NVAF). Read more...

TOPICS:

Profectus BioSciences Gets $9.5M DoD Funding for Ebola/Marburg Vaccine

October 31, 2014 10:00 am | News | Comments

Profectus BioSciences Inc. announced that the DoD through the Medical Countermeasure Systems-Joint Vaccine Acquisition Program (MCS-JVAP), a subordinate command of the Joint Program Executive Office for Chemical and Biological Defense, Edgewood, MD, has contracted the manufacture and IND-enabling preclinical testing of the Profectus trivalent Ebola/Marburg vaccine.  Read more...

TOPICS:

Specialized Therapeutics' Cancer Drug to be PBS Listed

October 31, 2014 9:33 am | News | Comments

Australian biopharmaceutical company Specialized Therapeutics Australia (STA) is announced Abraxane (nanoparticle albumin-bound paclitaxel) in combination with gemcitabine, will be reimbursed via the Pharmaceutical Benefits Scheme (PBS) for patients with metastatic pancreatic cancer from November 1. Read more...

TOPICS:
Advertisement

Making Lab-Grown Tissues Stronger

October 30, 2014 1:30 pm | News | Comments

Lab-grown tissues could one day provide new treatments for injuries and damage to the joints, including articular cartilage, tendons and ligaments. Read more..                                   

TOPICS:

TNIB to Start 90-Day HIV/AIDS Trial in Nigeria

October 30, 2014 1:16 pm | News | Comments

TNI BioTech Inc., a specialty pharmaceutical company involved in the manufacture, distribution and marketing of novel, patented therapies to combat chronic, life-threatening diseases through the activation and modulation of the body's immune system, through its wholly owned subsidiary TNI BioTech International Ltd., announces the initiation of a 90-day bridging trial in Nigeria of Lodonal in patients with HIV/AIDS. Read more...

TOPICS:

FDA Approves Generic Alzheimer's Drug

October 30, 2014 12:52 pm | News | Comments

TWi Pharmaceuticals Inc. announced that it has received final approval from the FDA on its Abbreviated New Drug Application (ANDA) for Donepezil Hydrochloride Tablets USP, 23 mg, the generic equivalent to Eisai Inc.'s Aricept 23mg. Read more...     

TOPICS:

‘Treasure in Saliva’ May Reveal Diseases Early Enough to Treat

October 30, 2014 12:34 pm | News | Comments

UCLA research could lead to a simple saliva test capable of diagnosing — at an early stage — diabetes and cancer, and perhaps neurological disorders and autoimmune diseases. Read more...

TOPICS:

Study Identifies Potential Treatment Target for Cocaine Addiction

October 30, 2014 12:16 pm | News | Comments

A study led by investigators from Massachusetts General Hospital and the Perelman School of Medicine at the University of Pennsylvania has identified a potential target for therapies to treat cocaine addiction. Read more...                        

TOPICS:

AstraZeneca's Diabetes Treatment Gets FDA Approval

October 30, 2014 12:00 pm | News | Comments

AstraZeneca announced that the FDA has approved once-daily Xigduo XR (dapagliflozin and metformin hydrochloride extended-release) for the treatment of adults with type 2 diabetes. Read more...                 

TOPICS:

Microsoft Unveils Fitness Gadget, Health Tracking

October 30, 2014 11:59 am | by Anick Jesdanun - AP Technology Writer | News | Comments

Microsoft is looking to challenge Apple and Google with its own system for consolidating health and fitness data from various fitness gadgets and mobile apps. Read more...               

TOPICS:

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading